Physician profile
Michael Wayt
NPI 1639164684
$7,706.66
in general payments reported to CMS, 2019-2025
44 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $801 · 2021: $1,956 · 2022: $1,252 · 2023: $1,526 · 2024: $1,090 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,094.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,034.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $721.69 | 2020-2024 | Mounjaro, Zepbound, Trulicity |
| Merck Sharp & Dohme LLC | $680.98 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Abbvie INC. | $603.15 | 2019-2024 | Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals Lp | $425.83 | 2021-2025 | Brilinta, Farxiga, Evusheld |
| Pfizer INC. | $400.00 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $382.67 | 2019-2025 | Seglentis, Zoryve, Livalo |
| Janssen Pharmaceuticals, INC | $378.13 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $350.39 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $317.03 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $283.96 | 2019-2023 | |
| Amgen INC. | $265.12 | 2019-2022 | |
| Daiichi Sankyo INC. | $203.36 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $179.67 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.52 | 2022-2024 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wayt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.